MARKET WIREInvesting.com • 5h ago
H.C. Wainwright reiterates Alumis stock rating on TYK2 dataInvesting.com report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.
Why ALMS Stock dropped -2.32% Today — RQD Quant Desk Flash
$6.73 -2.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $6.69
Alumis Inc. (ALMS) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $891.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ALMS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ALMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Alumis Inc. (NASDAQ: ALMS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $6.73 (-2.32% 1D, market cap $891.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ALMS compare to OBX and IVA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALMS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OBX (Obsidian Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $896.9M) and IVA (Inventiva S.A. American Depository Shares) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, ALMS leads on earnings multiple (N/A) while ALMS leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ALMS?
▼
Per ALMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001847367), Alumis Inc. generated $24.1M in revenue, -$243.3M in net income, and -$370.2M in free cash flow against $411.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $6.69 (-0.61%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-17.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALMS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY ALMS SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (37% of score)
FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 39.9 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (26% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$7.06-10.2% Next Q
27
Q2 (-2Q)Grade E$6.34+2.7% Next Q
24
Q3 (-1Q)Grade E$6.51+3.4% Next Q
22
CurrentGrade E$6.73-12% Hist 90D α
19
Trajectory: E (27) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ALMS Turnaround Squeeze
While ALMS currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.51) and Max Pain ($7.07) forces dealer call-delta covering toward $32.92.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALMS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALMS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ALMS Stock dropped -2.32% Today — RQD Quant Desk Flash
Alumis Inc. (ALMS) dropped -2.32% to $6.73, trading at 9% of its 52-week range ($4.39 – $31.35). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 9% of its 52-week range ($4.39 – $31.35) with RSI-14 at 39.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $6.73 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: ALMS Exhibits 3.63x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live ALMS Headlines & Catalysts
CATALYSTYahoo Finance • 8h ago
Is Almirall (BME:ALM) A Bargain As Lebrikizumab Data Strengthens Its Valuation Case?Yahoo Finance report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHInvesting.com • 11h ago
InvestingPro Fair Value flagged Alumis as overvalued before 46% fall By Investing.comInvesting.com report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREQuiver Quantitative • 14h ago
Alumis Reports Positive Phase 3 ONWARD Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis, Advances Toward 2026 NDA Filing | ALMS Stock NewsQuiver Quantitative report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 17h ago
Avoiding Lag: Real-Time Signals in (ALMS) MovementStock Traders Daily report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREPluang • 20h ago
Alvotech to present at multiple investor conferences in November 2026Pluang report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALMS)
- ✓Walkthrough of ALMS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ALMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.35%🛡️ HOLDING TREND SUPPORT
2026-11-02O $7.13H $7.13L $6.73C $6.73VOL 2.74M
RES: $40.82SUP: $4.82SMA50: $9.51SMA200: $21.33
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ALMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ALMS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ALMS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALMS)
Health Care Rank #998 of 1016
⚔️ OBX vs ALMS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ALMS vs. OBX, IVA, JBIO, ANRO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Alumis Inc. (ALMS) ranks #998 by composite RQD confidence (19/100, grade E) and #378 by equity capitalization ($891.8M). Within this direct 5-issuer industry benchmark cohort, ALMS leads on earnings valuation at N/A trailing P/E, while ALMS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IVA currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with ALMS at 19/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALMS
ACTIVE
Alumis Inc. | E | 19/100 | — | — | -35.0% | -2.32% | $891.8M | Benchmark Subject |
| OBX Obsidian Therapeutics Inc. | E | 34/100 | — | — | -35.0% | +1.86% | $896.9M | /obx-vs-alms → |
| IVA Inventiva S.A. American Depository Shares | D | 49/100 | — | — | — | -2.14% | $881.3M | /iva-vs-alms → |
| JBIO Jade Biosciences Inc. | E | 31/100 | — | — | -35.0% | -1.26% | $905.6M | /jbio-vs-alms → |
| ANRO Alto Neuroscience Inc. | D- | 35/100 | — | — | -35.0% | -3.71% | $921.0M | /anro-vs-alms → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001847367In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alumis Inc. (ALMS) reported GAAP revenue of $24.1M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$243.3M, operating cash flow of -$369.5M, and free cash flow of -$370.2M (-44.1% YoY). On the balance sheet, ALMS closed FY2025 with $411.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $24.1M | -$243.3M | -$369.5M | -$370.2M | $411.9M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$294.2M | -$255.1M | -$256.8M | $341.0M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$155.0M | -$130.0M | -$130.0M | — | — |
3. ALMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ALMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Alumis Inc. (NASDAQ: ALMS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $6.73 (-2.32% 1D, market cap $891.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
How does ALMS compare to OBX and IVA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALMS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OBX (Obsidian Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $896.9M) and IVA (Inventiva S.A. American Depository Shares) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, ALMS leads on earnings multiple (N/A) while ALMS leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ALMS?
Per ALMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001847367), Alumis Inc. generated $24.1M in revenue, -$243.3M in net income, and -$370.2M in free cash flow against $411.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ALMS trading relative to its 50-day, 200-day, and 52-week technical levels?
ALMS last traded at $6.73 (-2.32% on volume of 2,236,914 shares), positioning the stock -29.23% below its 50-day simple moving average ($9.51) and -68.45% below its 200-day simple moving average ($21.33). Across its 52-week range of $4.39 to $31.35, ALMS sits at the 8.7% percentile with a 14-day RSI of 39.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.89 to $7.57).
ALMS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ALMS stock moving today?
Why ALMS Stock dropped -2.32% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 19/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ALMS — Alumis Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:32:04Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ALMS carries an RQD Score of 19 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
- Fundamental Cash Engine: 0 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%. For an investor, this means the business is not currently generating returns on capital or free cash, so any valuation rests on future expectations rather than present cash output.
- Whale 13F Flow: 4 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The score is low, indicating limited supportive institutional flow in the source data.
- Insider Conviction: 3 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The low score signals weak insider-conviction signals in the source data.
- Macro Regime Fit: 7 / 20. Per the Roarable RQD rating, beta is 1.0 with a sector-sensitivity read. The stock is assessed as moderately exposed to broad market movement without a strong macro-fit advantage.
- Forensic Balance Sheet: 5 / 20. Per the Roarable RQD rating, Altman Z is 0.2, Piotroski F is 2/9, and Debt/Equity is 0.5. These readings point to elevated financial distress risk and weak balance-sheet quality.
Taken together, the rating frames ALMS as a high-risk name where the primary upside case depends on events outside current cash generation, while the forensic and cash-flow pillars flag significant downside risk. The prospective investor should weigh the valuation tradeoff: a market cap of $891.8M against negative ROIC and zero FCF yield means the price embeds expectations the reported financials do not yet support.
Business
Alumis Inc. (ALMS) is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company is categorized at a market capitalization of $0.9B. The source data does not specify its products, customers, or revenue model beyond the sector and industry classification. Per the SEC financials, FY 2025 revenue was $24.1M while FY 2024 revenue was $0.0M.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $24.1M | $-453.8M | $-243.3M | N/A | $-370.2M | $89.7M | N/A |
| FY 2024 | $0.0M | $-300.8M | $-294.2M | N/A | $-256.8M | $169.5M | N/A |
| FY 2023 | $0.0M | $-158.2M | $-155.0M | N/A | $-130.0M | N/A | N/A |
Per the SEC financials, operating margin and net margin are each -60%, and gross margin is 0%. Per the Roarable RQD rating, ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Reported cash declined from $169.5M in FY 2024 to $89.7M in FY 2025 while free cash flow remained deeply negative, indicating ongoing cash consumption.
Recent Catalysts & News Wire Analysis
- Positive Phase 3 data (Quiver Quantitative, GREEN/YELLOW): The headline reports positive Phase 3 ONWARD data for envudeucitinib in moderate-to-severe plaque psoriasis and advancement toward a 2026 NDA filing. This is the most substantive catalyst cited.
- Analyst reiteration on TYK2 data (Investing.com, YELLOW): H.C. Wainwright reiterated its rating on TYK2 data.
- Valuation risk flag (Investing.com, RED / RISK WATCH): An InvestingPro Fair Value headline flagged ALMS as overvalued before a 46% fall.
- Competitor-read headline (Yahoo Finance, GREEN / CATALYST): An article on Almirall's lebrikizumab data is related by theme but is not a direct ALMS event.
- Market-signal and conference items (YELLOW): A real-time signals article and an unrelated Alvotech investor-conference notice appear in the feed.
- Proprietary liquidity signal (Butterfly Supply-Chain Graph, BULLISH, severity 94): The signal reports a 3.63x True Net Liquidity elasticity and a Macro Tailwind Score of 96/100, with the Net Liquidity Index at $5,745.73B (-0.64% 4-week RoC; High-Yield OAS +2 bps). The regression correlation is r = -0.17, a weak statistical relationship that should temper reliance on the elasticity figure.
- Price action: Per the market data, the price is $6.89, down -3.37%, on volume of 2743493.
Open Questions
- What are ALMS's specific products, revenue sources, and customers, given that FY 2025 revenue of $24.1M is reported without a source description?
- What is the current cash runway, given cash of $89.7M against FY 2025 free cash flow of $-370.2M?
- What is the debt structure, since debt is N/A across all reported periods despite a stated Debt/Equity of 0.5?
- What are the timing and regulatory status of the envudeucitinib NDA filing referenced in the catalyst headline?
- What is the consensus analyst view and price target, which are absent from the source data?
ALMS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Alumis Inc. (ALMS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Investing.com • 5h ago
H.C. Wainwright reiterates Alumis stock rating on TYK2 data Investing.com report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 8h ago
Is Almirall (BME:ALM) A Bargain As Lebrikizumab Data Strengthens Its Valuation Case? Yahoo Finance report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Investing.com • 11h ago
InvestingPro Fair Value flagged Alumis as overvalued before 46% fall By Investing.com Investing.com report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Quiver Quantitative • 14h ago
Alumis Reports Positive Phase 3 ONWARD Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis, Advances Toward 2026 NDA Filing | ALMS Stock News Quiver Quantitative report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 17h ago
Avoiding Lag: Real-Time Signals in (ALMS) Movement Stock Traders Daily report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Pluang • 20h ago
Alvotech to present at multiple investor conferences in November 2026 Pluang report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ALMS Bull vs. Bear Conversation Board — What's Your Call at $6.73?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALMS 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $6.06 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ALMS (E • RQD 19/100) a Buy at $6.89?
Welcome to the ALMS (Alumis Inc.) Roar Pit. Current RQD Composite is 19/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $5.79 (-16.0%)
Spot @ $6.89 Pump the brakes on ALMS — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ALMS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Alumis Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $8.20 (+19.0%)
Spot @ $6.89 ALMS cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ALMS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $6.89 (52-wk range $4.39 - $31.35), any beat on forward guidance forces shorts and underweight funds to chase.